Introduction: Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poor effective.
Purpose: We conducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety of vandetanib in patients with progressive and symptomatic MTC.
Purpose: Vandetanib is well-tolerated in patients with advanced medullary thyroid carcinoma (MTC). Long-term outcomes and mechanisms of MTC progression have not been reported previously
A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy.
A new study shows that the chemotherapy drug vandetanib Caprelsa (vandetanib) from AstraZeneca, may extend life for some Thyroid Cancer...
The European Commission has granted marketing authorisation for Caprelsa (vandetanib) for the treatment of aggressive and symptomatic medullary Thyroid Cancer...
The CHMP has recommended vandetanib, as Caprelsa from AstraZeneca for the treatment of advanced, aggressive and symptomatic medullary thyroid cancer...
Containing relevant Learning Zones, guidelines, trials and news.
In updated guidance based on its latest review, NICE has announced that Caprelsa (vandetanib), from Genzyme/Sanofi, is not recommended, within...
Eli Lilly and Company announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib (Cabometyx) or vandetanib (Caprelsa) as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC)